Affimed (NASDAQ:AFMD) Short Interest Up 38.5% in December

Affimed (NASDAQ:AFMD) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 846,900 shares, a growth of 38.5% from the November 30th total of 611,400 shares. Approximately 6.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 253,700 shares, the days-to-cover ratio is currently 3.3 days.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Stifel Nicolaus lowered their price target on Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a research report on Friday, November 15th. Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a research note on Tuesday, November 19th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Affimed in a research report on Tuesday, December 10th. Finally, Wells Fargo & Company lowered their target price on Affimed from $20.00 to $15.00 and set an “overweight” rating for the company in a research note on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $13.50.

Affimed Stock Down 3.1 %

Affimed stock traded down $0.04 during mid-day trading on Monday, hitting $1.25. 81,815 shares of the company’s stock were exchanged, compared to its average volume of 289,498. Affimed has a fifty-two week low of $1.14 and a fifty-two week high of $8.95. The company’s 50 day simple moving average is $2.72 and its 200-day simple moving average is $3.84. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.93 and a current ratio of 1.93.

Institutional Investors Weigh In On Affimed

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Choreo LLC acquired a new stake in shares of Affimed in the second quarter valued at approximately $54,000. Jane Street Group LLC bought a new position in Affimed in the third quarter valued at $44,000. FMR LLC increased its stake in Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 4,086 shares during the last quarter. Intellectus Partners LLC lifted its position in Affimed by 12.2% during the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after buying an additional 10,250 shares in the last quarter. Finally, Point72 Asset Management L.P. lifted its position in Affimed by 4.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after buying an additional 15,108 shares in the last quarter. Institutional investors and hedge funds own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.